Advances in synthetic biology and AI-enabled design tools have rapidly expanded access to DNA synthesis, increasing both the benefits and the risks of misuse. Screening practices for DNA orders and customers remain uneven across providers and countries, creating gaps in global biosecurity and undermining trust in responsible providers. Without coordinated international approaches, fragmented standards risk leaving critical vulnerabilities in the global bioeconomy.